Anders Lund

Today I'm proud to announce that BIOKOL has delivered Rainbow's first 1,000-year permanence credits. Biokol.se, a pioneering biochar project in Sweden, is now validated under the Rainbow Standard, representing our first credit issuance and one of the first market issuances for biochar with this permanence horizon. This major milestone makes BIOKOL one of the first projects globally to meet rigorous certification standards that align with the latest research on biochar carbon removal permanence. Project highlights: BIOKOL brings together small-scale Swedish producers using pyrolysis technology to turn sustainably sourced forestry residues into biochar. Each tonne locks away 2.6 tonnes of CO2 equivalent in stable form, long-term. The project also delivers meaningful co-benefits: → 𝗟𝗶𝗳𝗲 𝗼𝗻 𝗹𝗮𝗻𝗱: applying biochar at 8 tonnes of biochar/hectare on farms raises average yields by 13% while locking carbon into the soil (which restores soil health and combats soil degradation) → 𝗟𝗼𝘄𝗲𝗿 𝗮𝗴𝗿𝗶𝗰𝘂𝗹𝘁𝘂𝗿𝗮𝗹 𝗲𝗺𝗶𝘀𝘀𝗶𝗼𝗻𝘀: biochar replaces conventional fertilizer, cutting nitrous oxide by at least 12% → 𝗙𝗼𝘀𝘀𝗶𝗹-𝗳𝗿𝗲𝗲 𝗲𝗻𝗲𝗿𝗴𝘆: the project powers every operation at both project sites with electricity certified as 100% renewable, delivering a fossil-free energy mix and promoting renewable energy → 𝗟𝗼𝗰𝗮𝗹 𝗰𝗼𝗺𝗺𝘂𝗻𝗶𝘁𝘆 𝗶𝗺𝗽𝗮𝗰𝘁: BIOKOL's distributed model reduces transport distances and supports rural economies with quality jobs This is the kind of project we need for real carbon removal and climate impact, now. Rainbow is proud to have BIOKOL in our portfolio of projects meeting high standards for scientific rigor, measurable climate impact, and local co-benefits. Fantastic work to the BIOKOL team! Photo courtesy of BIOKOL - link to Project Registry page below

144

12 Kommentarer

Delivering at scale: the evolution of biologics manufacturing in Denmark "Success in this field is built on trust, shared purpose, and the ability to work together toward a common goal." Kasper Møller, Chief Technical Officer and General Manager of AGC Biologics Denmark, shares with PharmaBoardroom’s Joseph Kun how AGC’s Copenhagen site has become a global anchor for the company’s protein biologics operations. With over two decades of local expertise, the facility now supports more than 30 programmes across development and commercial stages. Møller reflects on AGC Biologics’ strategic expansion, from doubling mammalian capacity to integrating AI and automation into manufacturing design. He also outlines the company’s sustainability push, with Copenhagen leading the charge on environmental reporting and operational responsibility. As demand rises for flexible, high-quality CDMO partners, AGC’s Danish operations are scaling with a long-term view, positioning the site as one of Europe’s most advanced hubs for single-use biomanufacturing. Read the full conversation at https://lnkd.in/gMqAxqus and stay tuned for our full Denmark country report, coming soon

105

1 Kommentar

From chicken alternatives to CO₂-eating microbes- congrats to our researchers at DTU Biosustain who have won Innovation Grants from the Novo Nordisk Foundation!👏 Here is what they will work on👇 🔬 Onur Kırtel Onur is engineering hyperstable enzymes that thrive under extreme industrial conditions found in carbon capture, utilization and storage.His team will use directed evolution to discover biocatalysts that survive heat, solvents and high pH - opening up possibilities for sustainable CO₂ conversion: 💬 “The project will allow us to evolve robust enzymes for CCUS, advancing directed evolution and unlocking enzyme families with untapped industrial potential.” 🧫 Emil Damgaard Jensen Emil’s team will expand a yeast-based biotechnology platform to identify vaccine candidates against fungal pathogens.Using high-throughput screening with yeast surface display, his team’s research could lead to safer, more effective antifungal vaccine candidates. 💬 “This is an outstanding opportunity to mature one of our established yeast-based cell-cell communication platforms towards commercialization for benefitting people and society.” 🥬 Leonie Johanna Jahn Leonie’s project is transforming a food sidestream into a sustainable chicken alternative.With the product already developed and nutritionally characterized, the next step is ensuring food safety, shelf life, and scalability - bringing this climate-friendly food closer to real world applications. 💬 “This grant will allow us to evaluate safety and production parameters of our chicken alternative and create a solid knowledge foundation for potential next steps.” 🧪 Enrico Orsi Enrico is scaling up a microbial bioprocess that turns CO₂ and renewable energy into valuable chemical building blocks -a potential game-changer for the packaging industry.His team will move from lab-scale to pilot-scale production in advanced bioreactors. 💬 “It’s a great opportunity to bridge the gap between strain engineering and process development and essential for real-world application.” 🧬 Daniel Volke Daniel’s team has invented a cell-free, ultra-high-throughput screening system to rapidly discover new enzymes. This innovation bypasses the need for living cells, allowing for faster, more resource-efficient selection of enzyme candidates with industrial potential. 💬 “This allows us to demonstrate the broad applicability of our cell-free enzyme screening platform, which combines speed, scalability and reduced resource input -paving the way toward market-ready biocatalyst discovery pipelines.” 🌿 Lei Yang Lei uses microbial fermentation to enhance the nutritional profile of plant-based diets.Her project targets essential nutrients often lacking in alternative proteins-supporting healthier, more complete diets that reduce reliance on animal-based food. 💬 “We anticipate that more complete nutritional profiles of alternative foods will accelerate broad market adoption and reduce the environmental impact of food systems.”

286

19 Kommentarer

🔬 Driving innovation in molecular diagnostics for ATMP With a decades-long track record in molecular analysis, Mikael Kubista—a Swedish researcher and entrepreneur—has founded Precision BioAnalytics, a new company based at GoCo Health Innovation City in Mölndal. The company develops more sensitive and reliable molecular diagnostics to support research, clinical diagnostics, and the development of cell and gene therapies. One area of particular promise is the earlier detection of infectious diseases like tuberculosis, where more accessible and precise diagnostics could have global impact. 🧪 Precision BioAnalytics is strategically connected to the Swedish ATMP innovation cluster through collaborations with Göteborgs universitet , Sahlgrenska Universitetssjukhuset, Chalmers tekniska högskola, AstraZeneca, and CCRM Nordic, which supports the field with infrastructure for clinical-grade manufacturing. The team’s ambition is to strengthen Sweden’s position in molecular diagnostics—an essential component in enabling safe and effective advanced therapies. 🔗 Read more: https://lnkd.in/dPxKWK32 #ATMP #MolecularDiagnostics #GeneTherapy #CellTherapy #LifeScienceSweden #GoCoHealthInnovationCity #PrecisionBioAnalytics #CCRMNordic #ATMP2030 #SwedishInnovation

61

3 Kommentarer

We are excited to share a new research publication from our Innovation Feed team, conducted in collaboration with our partners at Nofima, NMBU - Norwegian University of Life Sciences and BioMar. This study provides the first evidence that early-phase dietary protein enrichment can enhance resilience, welfare, and fillet quality, mitigating long-term issues like eye defects, soft flesh, gaping, and melanin spots, indicating its potential as a nutritional strategy to enhance production outcomes in Arctic salmon farming. -         These results are very encouraging. As we expand our farming operations in Arctic regions, gaining deeper insights into how nutrient needs vary with the seasons will help us enhance both operational performance and animal health and welfare, says Tibiábin Benítez-Santana. Cermaq’s Global Feed and Nutrition Manager Turid Mørkøre, Eunice Efua Boahemaa-Kobil, Trond M. Kortner, Elvis Chikwati, Vegard Denstadli, Thomas Larsson, Tibiábin Benítez-Santana, and Olai Einen. https://lnkd.in/dgz5sxQU

183

7 Kommentarer

DNB Carnegie acted as joint global coordinator and joint bookrunner in the directed share issue of USD 71 million in Hansa Biopharma. The financing round was multiple times oversubscribed at the final offer price and had strong support from new shareholders such as Polar Capital, alongside existing shareholders such as Redmile Group. Hansa Biopharma is a pioneering commercial-stage biopharmaceutical company on a mission to develop and commercialize innovative, lifesaving and life altering treatments for patients with rare immunological conditions. Hansa has developed a first-in-class IgG antibody cleaving enzyme therapy, which has been shown to enable kidney transplantation in highly sensitized patients.

78

Professor receives DKK 10 million grant to improve cirrhosis treatment Professor Peter Jepsen from the Department of Clinical Medicine has secured a DKK 10 million grant from the Novo Nordisk Foundation to improve cirrhosis treatment through better collaboration between hospital and general practitioners (GPs). Currently, cirrhosis patients are treated almost exclusively in hospitals despite regular GP contact. Peter Jepsen's project "Shared care for patients with cirrhosis" will test new models to bring quality care closer to patients' homes through two pilot studies in Denmark and England. "We need to improve and change the treatment of cirrhosis - and to do that, we need to involve both patients and GPs in the process," says Peter Jepsen. The research will explore GP-led screening, preventive care, and digital communication via e-Boks to improve the collaboration between healthcare sectors. We look forward to seeing the results of the study. Learn more about the research by visiting the faculty website. 📷: Mimosa Foto.

243

34 Kommentarer